Monoclonal antibodies are molecules made in a lab that are designed to act as replacement antibodies and repair, improve, change, or imitate the immune system's attack on undesirable cells, such as cancer cells. Different mechanisms are used by monoclonal antibodies to accomplish their goals. A particular medicine may really have many mechanisms of action. Numerous monoclonal antibodies have received approval to treat a wide range of cancer types. New medications and novel applications for already available monoclonal antibodies are being studied in clinical studies. Certain monoclonal antibodies (MABs) are an immunotherapy technique. They function by activating the immune system and assisting it in fighting cancer. The immune system's effects of MABs are discussed on this page. Certain monoclonal antibodies (MABs) are an immunotherapy technique. Certain monoclonal antibodies (MABs) are an immunotherapy technique. They function by activating the immune system and assisting it in fighting cancer. The immune system's effects of MABs are discussed on this page. Some MABs function in a more focused manner. They can, for instance, disrupt signals that instruct cancer cells to proliferate. More information about this may be found in our targeted cancer medication information. A MAB functions by identifying and locating certain proteins on cells. Some focus on cancer cells, while others target immune system cells' proteins. Every MAB recognises a different protein. Depending on the protein they are targeting, they operate in various ways. Certain MABs cause the immune system to go for and kill cancer cells. Cancer cells are aberrant, but because they arise from normal cells, the immune system may have trouble identifying them. Some MABs bind to cancer cells, making it simpler for immune system cells to locate those cells. ADCC, or antibody-dependent cell-mediated cytotoxicity, is the name of this process.